Barclays Capital began coverage on shares of Regeneron Pharms (NASDAQ: REGN) in a report issued on Thursday. The firm issued an overweight rating and a $194.00 target price on the stock.
Shares of Regeneron Pharms traded up 0.14% during mid-day trading on Thursday, hitting $171.967. Regeneron Pharms has a 52 week low of $102.82 and a 52 week high of $188.95. The stock’s 50-day moving average is currently $169.. The company has a market cap of $16.621 billion and a P/E ratio of 25.42.
Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a buy rating on shares of Regeneron Pharms in a research note to investors on Wednesday, February 27th. Separately, analysts at Zacks reiterated a neutral rating on shares of Regeneron Pharms in a research note to investors on Monday, February 18th. They now have a $173.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a buy rating on shares of Regeneron Pharms in a research note to investors on Monday, February 11th. They now have a $190.00 price target on the stock.
Nine investment analysts have rated the stock with a buy rating, one has given an overweight rating, and nine have assigned a hold rating to the company. The stock presently has a consensus rating of overweight and a consensus target price of $185.21.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
